Navigation Links
Mayo Clinic researchers identify new enzyme to fight Alzheimer's disease
Date:9/17/2012

JACKSONVILLE, Fla. An enzyme that could represent a powerful new tool for combating Alzheimer's disease has been discovered by researchers at Mayo Clinic in Florida. The enzyme known as BACE2 destroys beta-amyloid, a toxic protein fragment that litters the brains of patients who have the disease. The findings were published online Sept. 17 in the science journal Molecular Neurodegeneration.

Alzheimer's disease is the most common memory disorder. It affects more that 5.5 million people in the United States. Despite the disorder's enormous financial and personal toll, effective treatments have not yet been found.

The Mayo research team, led by Malcolm A. Leissring, Ph.D., a neuroscientist at Mayo Clinic in Florida, made the discovery by testing hundreds of enzymes for the ability to lower beta-amyloid levels. BACE2 was found to lower beta-amyloid more effectively than all other enzymes tested. The discovery is interesting because BACE2 is closely related to another enzyme, known as BACE1, involved in producing beta-amyloid.

"Despite their close similarity, the two enzymes have completely opposite effects on beta-amyloid BACE1 giveth, while BACE2 taketh away," Dr. Leissring says.

Beta-amyloid is a fragment of a larger protein, known as APP, and is produced by enzymes that cut APP at two places. BACE1 is the enzyme responsible for making the first cut that generates beta-amyloid. The research showed that BACE2 cuts beta-amyloid into smaller pieces, thereby destroying it, instead. Although other enzymes are known to break down beta-amyloid, BACE2 is particularly efficient at this function, the study found.

Previous work had shown that BACE2 can also lower beta-amyloid levels by a second mechanism: by cutting APP at a different spot from BACE1. BACE2 cuts in the middle of the beta-amyloid portion, which prevents beta-amyloid production.

"The fact that BACE2 can lower beta-amyloid by two distinct mechanisms makes this enzyme an especially attractive candidate for gene therapy to treat Alzheimer's disease," says first author Samer Abdul-Hay, Ph.D., a neuroscientist at Mayo Clinic in Florida.

The discovery suggests that impairments in BACE2 might increase the risk of Alzheimer's disease. This is important because certain drugs in clinical use for example, antiviral drugs used to treat human immunodeficiency virus (HIV) work by inhibiting enzymes similar to BACE2.

Although BACE2 can lower beta-amyloid by two distinct mechanisms, only the newly discovered mechanism beta-amyloid destruction is likely relevant to the disease, the researchers note. This is because the second mechanism, which involves BACE2 cutting APP, does not occur in the brain. The researchers have obtained a grant from the National Institutes of Health to study whether blocking beta-amyloid destruction by BACE2 can increase the risk for Alzheimer's disease in a mouse model of the disease.


'/>"/>

Contact: Kevin Punsky
punsky.kevin@mayo.edu
904-953-2299
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Clinic-based community program helps with childhood obesity
2. PARP inhibitors may have clinical utility in HER2-positive breast cancers
3. Maturitas publishes clinical guide on low-dose vaginal estrogens for vaginal atrophy
4. New national clinical trials network for neurological disorders to foster cutting-edge treatments
5. New clinical guidelines for managing hypothyroid disease presented in Thyroid Journal
6. Epigenetics emerges powerfully as a clinical tool
7. Mayo Clinic suicide prevention expert outlines new steps to tackle military suicide
8. Physicians empathy directly associated with positive clinical outcomes, confirms large study
9. When clinicians and researchers look outside the box
10. Suicide prevention, telemedicine among topics at Mayo Clinic Transform 2012
11. Joint EACPR and AHA statement empowers health care professional to use Clinical Cardiopulmonary Exercise Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... METTLER TOLEDO has ... personnel have a basic understanding of the techniques they use so they can ... help them reduce waste and rework to create a leaner overall lab experience. ...
(Date:2/9/2016)... ... ... i2i Systems, an early innovator and developer of population health management technology, ... report, Population Health Management 2015: How Far Can Your Vendor Take You? , ... The latest KLAS Report, leveraging over 200 user interviews, shines a light on ...
(Date:2/8/2016)... ... 08, 2016 , ... Brenntag Specialties, Inc.(BSI) , is ... & Beverage and Dietary Supplement market segments across the western ... geographies east of the Rocky Mountains since 2012. Consistent performance in business ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... L top-load case packer for pouches, bags, and flow wrapped products at WestPack ... co-packers and specialty product manufacturers step up to semi-automatic or fully-automatic case packing ...
(Date:2/8/2016)... ... February 08, 2016 , ... Local insurance agency ... Venice, FL area, has initiated a fundraiser for a two year old little ... days after Christmas. To support this beautiful child who is facing life’s journey ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... February 9, 2016 ... heute den Abschluss eines Kooperationsvertrags mit 10x ... Lösungen in den Bereichen Next-Generation-Sequencing (NGS), Single-Cell-Biology ... ; Frankfurt Prime Standard: QIA) gab heute ... für die Entwicklung und Förderung umfassender Lösungen ...
(Date:2/9/2016)... ORLANDO, Florida , February 9, 2016 /PRNewswire/ ... QIA) today announced a collaboration with 10x Genomics ... sequencing (NGS), single-cell biology and bioinformatics. --> ... announced a collaboration with 10x Genomics to develop ... single-cell biology and bioinformatics. --> QIAGEN ...
(Date:2/9/2016)... -- Mast Therapeutics, Inc. (NYSE MKT: MSTX), a ... and heart failure, today announced that it intends to offer ... in an underwritten public offering.  The offering is subject to ... as to whether or when the offering may be completed, ... offering.   --> --> ...
Breaking Medicine Technology: